Reading the launch
One of the eight brand names Eli Lilly trademarked on Sept 2 for retatrutide, the triple-agonist obesity shot that beat Zepbound in trials. Retatrutide already ran to $841k on LLY. Whichever name Lilly picks is the next headline. Paired with LLY.
Reading trades.